Practice Patterns in the Use of Anti-Tumor Necrosis Factor Alpha Agents in the Management of Crohn’s Disease: A US National Practice Survey Comparing Experts and Non-Experts

Author： Swaminath Arun   Lebwohl Benjamin   Capiak Kristina   Present Daniel  

Publisher： Springer Publishing Company

ISSN： 0163-2116

Source： Digestive Diseases and Sciences, Vol.56, Iss.4, 2011-04, pp. : 1160-1164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Tumor Necrosis Factor Nonresponders in Crohn’s Disease: Therapeutic Strategies

By  

Digestive Diseases, Vol. 27, Iss. 3, 2009-09 ,pp. : 351-357

Karger

Access to resources Recommend Favorite

Long-Term Partial Remission of AutoImmune Thrombocytopenia in a Patient Treated with the Anti-Tumor Necrosis Factor-Alpha Antibody Infliximab for Refractory Fistulizing Crohn’s Disease

By  

Digestion, Vol. 78, Iss. 4, 2008-12 ,pp. : 195-200

Karger

Access to resources Recommend Favorite

Tumor Necrosis Factor-Alpha in Ileal Mast Cells in Patients with Crohn’s Disease

By  

Digestion, Vol. 61, Iss. 1, 2000-02 ,pp. : 68-76

Karger

Access to resources Recommend Favorite

Suspected de novo Hepatitis B in a Patient Receiving Anti-Tumor Necrosis Factor Alpha Therapy for the Treatment of Crohn's Disease

By  

Case Reports in Gastroenterology, Vol. 8, Iss. 1, 2014-01 ,pp. : 44-50

Karger

Access to resources Recommend Favorite

Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease

By  

Digestion, Vol. 88, Iss. 1, 2013-06 ,pp. : 17-19

Karger

Access to resources Recommend Favorite